Prilocaine EP Impurity F

Liquid–Liquid Miscibility Gaps in Drug–Water Binary Systems: Crystal Structure and Thermodynamic Properties of Prilocaine and the Temperature–Composition Phase Diagram of the Prilocaine–Water System
Ivo B. Rietveld, Marc-Antoine Perrin, Siro Toscani, Maria Barrio, Beatrice Nicolai, Josep-Lluis Tamarit, and René Ceolin
Mol. Pharmaceutics 2013, 10, 4, 1332–1339
 
LC Determination of Lidocaine and Prilocaine Containing Potential Risky Impurities and Application to Pharmaceuticals
Mohammad Abdul-Azim Mohammad
Chromatographia volume 70, pages563–568(2009)
 
Determination of prilocaine HCL in bulk drug and pharmaceutical formulation by GC-NPD method
alptug atila, yucel kadioglu
Chemical Industry and Chemical Engineering Quarterly 19(2)
 
Simultaneous quantification of lidocaine and prilocaine in human plasma by LC-MS/MS and its application in a human pharmacokinetic study
Siva SankaraRao, Yadlapalli, Naresh KumarKatari, Surendra Babu, Manabolu Surya, Vijaya KumariKarra, VinuthaKommineni, Sreekantha B.Jonnalagadda
Practical Laboratory Medicine Volume 17, November 2019, e00129

Prilocaine EP Impurity F is chemically (R)-N-phenyl-2-(propylamino)propanamide. Prilocaine EP Impurity F is supplied with detailed characterization data compliant with regulatory guideline. Prilocaine EP Impurity F can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Prilocaine.

The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.